 CNS Pharmaceuticals, Inc. NASDAQ: CNSP CNS or the Company, a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that CEO, John M. Climaco, will be issuing a shareholder webinar on August 13th, 2020 at 4:30pm ET to discuss business developments and the progress of the Companys lead candidate Berubicin, novel DNA-binding agent WP1244 and development agreement with WPD Pharmaceuticals for WP1122. 